Search the Site
Follow TheCancerLetter on Twitter
join our mailing list

Enter your name and email address to receive an update when we post new content.

IP Login

 

The Cancer Letter Inc.
PO Box 9905
Washington
DC 20016
Tel: 202-362-1809
Fax: 202-379-1787
publication date: Nov 8, 2013
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.

More than 230,000 people—including 82 Texas state lawmakers—petitioned BioMarin Pharmaceutical Inc. to provide its investigational drug to a Austin attorney afflicted with stage IIIC ovarian cancer.

 

The story was getting massive coverage.

 

Television networks, newspapers and social media were focusing on the patient’s plight and BioMarin’s reluctance to provide the agent, BMN-673, a PARP inhibitor that stops DNA repair in cancer cells.

 

Several supporters got hold of the email address of the company’s CEO, Jean-Jacques Bienaimé, and contacted him directly on behalf of 45-year-old Andrea Sloan, the attorney who was trying to get the drug through compassionate use.



To access this members-only content, please log in.

If you're not a subscriber why not join today?

If you believe you should be able to view this area but cannot log in, then please contact us and we will try to rectify this issue as soon as possible.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Letter